Estimated Inpatient Hospital Stay in Individual Wards: Guidelines on Radiation Safety after Radioiodine Therapy

Radionuclide therapy safety requirements are regulated by the Russian Radiation Safety Standards (RRSS), which state the maximum allowed radionuclide activity in the body and the equivalent dose rate (EDR) of gamma radiation. Therefore, it is necessary to estimate the time of an inpatient hospital stay in specially designed radionuclide therapy wards. The article presents the findings of individual 131I biokinetics studies in 64 patients admitted to radioiodine therapy of thyrotoxicosis and differentiated thyroid cancer. We developed a method to calculate the time interval to reach the EDR of 20μSv/h and the recommended EDR of 3 and 0.3μSv/h for adults and children, respectively. It is based on the measurement of the 131I excretion constant. Keywords: Radioiodine therapy, Radiation safety, Guidelin

A Common Origin of Neutralino Stars and Supermassive Black Holes

To account for the microlensing events observed in the Galactic halo, Gurevich, Zybin, and Sirota have proposed a model of gravitationally bound, noncompact objects with masses of 0.01-1M_\odot. These objects are formed in the expanding Universe from adiabatic density perturbations and consist of weakly interacting particles of dark matter, for example, neutralinos. They assumed the perturbation spectrum on some small scale to have a distinct peak. We show that the existence of this peak would inevitably give rise to a large number of primordial black holes (PBHs) with masses of \sim10^5M_\odot at the radiation-dominated evolutionary stage of the Universe. Constraints on the coefficient of nonlinear contraction and on the compactness parameter of noncompact objects were derived from constraints on the PBH number density. We show that noncompact objects can serve as gravitational lenses only at a large PBH formation threshold, \delta_c > 0.5, or if noncompact objects are formed from entropic density perturbations.Comment: 17 pages, 4 figure

Ten Years of Pathway Analysis: Current Approaches and Outstanding Challenges

Pathway analysis has become the first choice for gaining insight into the underlying biology of differentially expressed genes and proteins, as it reduces complexity and has increased explanatory power. We discuss the evolution of knowledge base–driven pathway analysis over its first decade, distinctly divided into three generations. We also discuss the limitations that are specific to each generation, and how they are addressed by successive generations of methods. We identify a number of annotation challenges that must be addressed to enable development of the next generation of pathway analysis methods. Furthermore, we identify a number of methodological challenges that the next generation of methods must tackle to take advantage of the technological advances in genomics and proteomics in order to improve specificity, sensitivity, and relevance of pathway analysis

Computational solutions for omics data

High-throughput experimental technologies are generating increasingly massive and complex genomic data sets. The sheer enormity and heterogeneity of these data threaten to make the arising problems computationally infeasible. Fortunately, powerful algorithmic techniques lead to software that can answer important biomedical questions in practice. In this Review, we sample the algorithmic landscape, focusing on state-of-the-art techniques, the understanding of which will aid the bench biologist in analysing omics data. We spotlight specific examples that have facilitated and enriched analyses of sequence, transcriptomic and network data sets.National Institutes of Health (U.S.) (Grant GM081871